96. クローン病
[臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210]
Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03220841 (ClinicalTrials.gov) | October 9, 2017 | 6/7/2017 | Stricture Definition and Treatment (STRIDENT) Drug Therapy Study | Stricture Definition and Treatment (STRIDENT) Drug Therapy Study | Crohn Disease;Inflammatory Bowel Diseases;Stricture; Bowel | Drug: Adalimumab Injection;Drug: Thiopurine;Procedure: Endoscopic balloon dilatation | St Vincent's Hospital Melbourne | Australasian Gastro Intestinal Research Foundation;AbbVie | Active, not recruiting | 18 Years | N/A | All | 78 | Phase 4 | Australia |
2 | EUCTR2016-003321-42-NL (EUCTR) | 18/01/2017 | 08/12/2016 | Stepwise extention of the adalimumab injection interval in patients with stable Crohn's disease. | Lengthening Adalimumab Dosing Interval in quiescent Crohn’s disease patients: the LADI study. | Crohn's disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: Humira (adalimumab) Product Name: Adalimumab INN or Proposed INN: ADALIMUMAB | Radboud University Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Phase 4 | Netherlands |